Overall, CT-388 has yielded promising results in terms of safety, tolerability, and efficacy for the treatment of obesity, with data supporting further clinical development and exploration at higher doses
Mounjaro, presented by Eli Lilly, stands out with tirzepatide, a dual agonist for GLP-1 and GIP receptors, enriching the metabolic regulation landscape by combining GLP-1s appetite control with GIPs metabolic advantages
If an untrained clinician prescribes GLP-1s without appropriate support, an individual could actually become sicker
When people eat substantially less, they often eat fewer nutrient-dense foods alongside the caloric reduction, leading to micronutrient shortfalls that standard blood panels will reveal
The cases are illustrative rather than representative